Sep 13, 2022 / 08:30PM GMT
Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst
Hello, everyone, and good afternoon, and welcome back to H.C. Wainwright's 24th Annual Global Investment Hybrid Conference. My name is Patrick Trucchio. I'm a senior healthcare analyst at H.C. Wainwright.
It's my pleasure to introduce our next presenter. I'd like to welcome Michael Amoroso, CEO; Derek Jantz, CSO; and Alan List, CMO of Precision BioSciences, a clinical-stage gene-editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies.
So maybe if we could just begin with an overview of Precision's ARCUS platform, how it's differentiated versus other approaches in the field such as CRISPR.
Michael Amoroso - Precision BioSciences, Inc. - President & CEO
Yes, just a quick one, Patrick. And Wainwright, thanks for having us. We're excited to be with you. And I'm going to turn it over to our CSO and Co-Founder, Derek Jantz, for an overview on the organization.
Derek Jantz - Precision BioSciences, Inc. - Chief
Precision BioSciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 14, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers